Working… Menu

Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03495921
Recruitment Status : Active, not recruiting
First Posted : April 12, 2018
Last Update Posted : February 4, 2021
Information provided by (Responsible Party):
Gradalis, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : July 1, 2023